Optimizing Immunohistochemical Surrogate Panels for 1p/19q Codeletion in IDH-Mutant Adult Diffuse Gliomas: Diagnostic Performance of Vimentin and H3K27me3
- 1Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
- 2Department of Oncology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
- 3Department of Neurosurgery, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
Abstract
Background: Differentiating IDH-mutant astrocytomas from IDH-mutant, 1p/19q-codeleted oligodendrogliomas can be challenging due to overlapping histology, particularly in small samples. We evaluated whether quantitative expression of vimentin and H3K27me3 can serve as reliable surrogate markers for 1p/19q-codeletion status. Methods: A cohort of 71 adult IDH-mutant diffuse gliomas (34 astrocytomas, 37 oligodendrogliomas) was analyzed. Marker expressions were evaluated together with key histopathological features. Results: Diagnostic performance was assessed using receiver operating characteristic (ROC) curves, multivariable logistic regression, and hierarchical modeling. Both H3K27me3 positivity (≥30% cut-off; 96.97% sensitivity, 88.89% specificity) and vimentin positive area (≥40% cut-off; 100% sensitivity, 89.19% specificity) were significantly higher in astrocytomas than in oligodendrogliomas (p < 0.0001). Classical oligodendroglial features correlated with lower expression of both markers, whereas gemistocytes correlated with higher expression. Individual AUCs were high for ATRX (0.933), H3K27me3 (0.928), and vimentin (0.944). In multivariable regression containing both markers, vimentin proved to be the dominant predictor (p = 0.008), rendering H3K27me3 redundant (p = 0.725). Hierarchical regression showed that adding vimentin or H3K27me3 to ATRX individually significantly improved performance (AUC = 0.994, p < 0.001). However, adding H3K27me3 to the ATRX + vimentin combination provided no significant improvement (p = 0.063). Conclusions: Vimentin loss and H3K27me3 loss are effective individual surrogate markers for 1p/19q-codeletion in adult IDH-mutant diffuse gliomas. However, multivariable and hierarchical regression modeling demonstrates that vimentin is the dominant predictor that renders H3K27me3 statistically redundant. A streamlined two-marker immunohistochemical panel combining ATRX and vimentin provides optimal diagnostic accuracy (AUC = 0.994) without requiring additional H3K27me3 testing, offering an accessible workflow for routine neuropathology.
Related
- Diagnostic Accuracy of APTw and NOEw MRI Metrics for IDH Mutation and 1p/19q Codeletion Prediction in Gliomas
- A Rare Suprasellar Ependymoma With Negative Targeted Fusion Testing: Diagnostic Value of Histopathological, Immunohistochemical, and Ultrastructural Findings.
- Diagnostic value of CD4, CD8 and CD68 immunohistochemical profiling in EBUS-TBNA samples for differentiating sarcoidosis and tuberculosis.
- Transcranial Direct Current Stimulation and Cranial Electrotherapy Stimulation in Athletes: Optimizing Athletic Performance and Sleep Quality Through Neuromodulation
- Functional acuity score as a surrogate of reading performance in low vision: A Japanese disability evaluation cohort study
BibTeX
@article{lockli2026optimizing,
title = {{Optimizing Immunohistochemical Surrogate Panels for 1p/19q Codeletion in IDH-Mutant Adult Diffuse Gliomas: Diagnostic Performance of Vimentin and H3K27me3}},
author = {Eliza M. Löckli and Rachael S. Ninan and Krisztina A. Chalupa and Attila Mokánszki and Basil Habash and Ingrid Balogh and László Novák and Emanuel Gutema and Judit Bedekovics},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213588},
url = {https://www.mdpi.com/2072-6694/18/21/3588},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Optimizing Immunohistochemical Surrogate Panels for 1p/19q Codeletion in IDH-Mutant Adult Diffuse Gliomas: Diagnostic Performance of Vimentin and H3K27me3
AU - Eliza M. Löckli
AU - Rachael S. Ninan
AU - Krisztina A. Chalupa
AU - Attila Mokánszki
AU - Basil Habash
AU - Ingrid Balogh
AU - László Novák
AU - Emanuel Gutema
AU - Judit Bedekovics
PY - 2026
DA - 2026/11/08
JO - Cancers
DO - 10.3390/cancers18213588
UR - https://www.mdpi.com/2072-6694/18/21/3588
AB - Background: Differentiating IDH-mutant astrocytomas from IDH-mutant, 1p/19q-codeleted oligodendrogliomas can be challenging due to overlapping histology, particularly in small samples. We evaluated whether quantitative expression of vimentin and H3K27me3 can serve as reliable surrogate markers for 1p/19q-codeletion status. Methods: A cohort of 71 adult IDH-mutant diffuse gliomas (34 astrocytomas, 37 oligodendrogliomas) was analyzed. Marker expressions were evaluated together with key histopathological features. Results: Diagnostic performance was assessed using receiver operating characteristic (ROC) curves, multivariable logistic regression, and hierarchical modeling. Both H3K27me3 positivity (≥30% cut-off; 96.97% sensitivity, 88.89% specificity) and vimentin positive area (≥40% cut-off; 100% sensitivity, 89.19% specificity) were significantly higher in astrocytomas than in oligodendrogliomas (p < 0.0001). Classical oligodendroglial features correlated with lower expression of both markers, whereas gemistocytes correlated with higher expression. Individual AUCs were high for ATRX (0.933), H3K27me3 (0.928), and vimentin (0.944). In multivariable regression containing both markers, vimentin proved to be the dominant predictor (p = 0.008), rendering H3K27me3 redundant (p = 0.725). Hierarchical regression showed that adding vimentin or H3K27me3 to ATRX individually significantly improved performance (AUC = 0.994, p < 0.001). However, adding H3K27me3 to the ATRX + vimentin combination provided no significant improvement (p = 0.063). Conclusions: Vimentin loss and H3K27me3 loss are effective individual surrogate markers for 1p/19q-codeletion in adult IDH-mutant diffuse gliomas. However, multivariable and hierarchical regression modeling demonstrates that vimentin is the dominant predictor that renders H3K27me3 statistically redundant. A streamlined two-marker immunohistochemical panel combining ATRX and vimentin provides optimal diagnostic accuracy (AUC = 0.994) without requiring additional H3K27me3 testing, offering an accessible workflow for routine neuropathology.
SN - 2072-6694
ER -